Home
Clinical Trials
Study to Assess the Safety an...

Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

Last Updated: 2025-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2324 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-04

Study Completion Date

2025-06-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study will evaluate how safe risankizumab is for the treatment of plaque psoriasis or psoriatic arthritis and to assess change in disease symptoms.

Risankizumab is an approved drug for the treatment of psoriasis and psoriatic arthritis. Around 3000 adult participants with a moderate to severe plaque psoriasis or psoriatic arthritis who had been prescribed risankizumab by their doctor will be enrolled in this study in multiple sites across Korea. The sample size for this study is a requirement by local authorities.

Participants will receive risankizumab prefilled syringe for injection for 52 weeks as prescribed by their physician.

There is expected to be no additional burden for participants in this study. All study visits will occur during routine clinical practice and participants will be followed for 52 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

NCT06333860

Moderate Plaque Psoriasis

ACTIVE_NOT_RECRUITING PHASE4

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

NCT05969223

Genital Psoriasis Scalp Psoriasis

COMPLETED PHASE4

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475

Psoriasis

COMPLETED PHASE4

Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity

NCT04722640

Psoriasis

UNKNOWN PHASE4

Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care

NCT04780516

Psoriasis

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Psoriatic Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moderate to Severe Plaque Psoriasis or Psoriatic Arthritis

Participants will receive risankizumab as prescribed by the physician in routine clinical practice.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Suitable for the treatment with risankizumab according to the approved local label.
* Voluntarily agree to participate in this study and sign informed consent.

Exclusion Criteria

\- Contraindications to risankizumab as listed on the approved local label.

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Inje University - Busan Paik Hospital /ID# 238911

Busan, Busan Gwang Yeogsi, South Korea

Site Status

Inje University Haeundae Hospital /ID# 238933

Busan, Busan Gwang Yeogsi, South Korea

Site Status

Pusan National University Hospital /ID# 238896

Busan, Busan Gwang Yeogsi, South Korea

Site Status

Dankook University Hospital /ID# 223995

Cheonan-si, Chungcheongnam-do, South Korea

Site Status

SoonChunHyang University Hospital Cheonan /ID# 238909

Cheonan-si, Chungcheongnam-do, South Korea

Site Status

Kyungpook National University Hospital /ID# 238915

Daegu, Daegu Gwang Yeogsi, South Korea

Site Status

Chungnam National University Hospital /ID# 223993

Daejeon, Daejeon Gwang Yeogsi, South Korea

Site Status

Konyang University Hospital /ID# 238899

Daejeon, Daejeon Gwang Yeogsi, South Korea

Site Status

Kangwon National University Hospital /ID# 238902

Chuncheon, Gang Weondo, South Korea

Site Status

Korea University Ansan Hospital /ID# 223989

Ansan-si, Gyeonggido, South Korea

Site Status

Soon Chun Hyang University Hospital Bucheon /ID# 238894

Bucheon-si, Gyeonggido, South Korea

Site Status

The Catholic University Of Korea, Bucheon St. Mary'S Hospital /ID# 270826

Bucheon-si, Gyeonggido, South Korea

Site Status

Hallym University Dongtan Sacred Heart Hospital /ID# 238927

Hwaseong, Gyeonggido, South Korea

Site Status

Dongguk University Ilsan Hospital /ID# 259337

Ilsan, Gyeonggido, South Korea

Site Status

Gachon University Gil Medical Center /ID# 262788

Incheon, Gyeonggido, South Korea

Site Status

Catholic Kwandong University International St.Mary's Hospital /ID# 262855

Incheon, Gyeonggido, South Korea

Site Status

CHA Bundang Medical Center /ID# 238916

Seongnam, Gyeonggido, South Korea

Site Status

Seoul National University Bundang Hospital /ID# 238900

Seongnam-si, Gyeonggido, South Korea

Site Status

Hallym University Sacred Heart Hospital /ID# 238913

Seoul, Gyeonggido, South Korea

Site Status

Hallym University Sacred Heart Hospital /ID# 238930

Seoul, Gyeonggido, South Korea

Site Status

The Catholic University Of Korea St. Vincent's Hospital /ID# 248371

Suwon, Gyeonggido, South Korea

Site Status

Ajou University Hospital /ID# 238920

Suwon, Gyeonggido, South Korea

Site Status

Uijeongbu Eulji Medical Center - Eulji University /ID# 259200

Uijeongbu-si, Gyeonggido, South Korea

Site Status

The Catholic University of Korea, Uijeongbu ST. Mary's Hospital /ID# 259201

Uijeongbu-si, Gyeonggido, South Korea

Site Status

The Catholic University of Korea, Uijeongbu ST. Mary's Hospital /ID# 259202

Uijeongbu-si, Gyeonggido, South Korea

Site Status

Yongin Severance Hospital /ID# 238925

Yŏngin, Gyeonggido, South Korea

Site Status

Daegu Catholic University Medical Center /ID# 238921

Daegu, Gyeongsangbuk-do, South Korea

Site Status

Keimyung University Dongsan Hospital /ID# 238932

Daegu, Gyeongsangbuk-do, South Korea

Site Status

Dongguk University Gyeongju Hospital /ID# 238923

Gyeongju, Gyeongsangbuk-do, South Korea

Site Status

Pusan National University Yangsan Hospital /ID# 259098

Yangsan, Gyeongsangnam-do, South Korea

Site Status

The Catholic University of Korea, Incheon St. Mary's Hospital /ID# 238934

Incheon, Incheon Gwang Yeogsi, South Korea

Site Status

Inha University Hospital /ID# 248373

Incheon, Incheon Gwang Yeogsi, South Korea

Site Status

Wonkwang University Hospital /ID# 238901

Iksan, Jeonrabugdo, South Korea

Site Status

Design Hospital /ID# 238929

Jeollabuk-do, Jeonrabugdo, South Korea

Site Status

Chosun University Hospital /ID# 238910

Gwangju, Jeonranamdo, South Korea

Site Status

Chonnam National University Hospital /ID# 259199

Gwangju, Jeonranamdo, South Korea

Site Status

Chungbuk National University Hospital /ID# 238891

Cheongju-si, North Chungcheong, South Korea

Site Status